Startup NGS-based Diagnostics Firm Guardant Health Raises $30M in Series B | GenomeWeb

NEW YORK (GenomeWeb) – Next-generation sequencing-based diagnostics firm Guardant Health today announced it raised $30 million in a Series B financing.

Khosla Ventures led the round and was joined by existing investor Sequoia Capital and new investor Pejman Mar Ventures.

The financing "will allow Guardant Health to accelerate the expansion of its commercial operations to support growing demand and ensure a distinctively high level of service for our physicians and patients," Guardant CEO and Co-Founder Helmy Eltoukhy said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.